Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
23 November 2021 | Story Leonie Bolleurs | Photo Tania Allen
Dr Jana Vermaas and Ketshepileone Matlhoko are working on research that leaves your washing clean and fresh without the use of any detergents, which is also beneficial to the environment.

Cold water or hot water? Omo or Skip? Laundry blues is a reality in most households and when you add stains to the equation, then what was supposed to be part of your weekly household routine, becomes frustrating and time consuming. 

Researchers at the University of the Free State (UFS) are conducting research that is putting a whole new environmentally friendly spin on laundry day.

Sustainability and environmental conservation

Dr Jana Vermaas, Lecturer in the Department of Sustainable Food Systems and Development at the UFS, is passionate about textiles and sustainability – almost a decade ago, she conducted a study on the efficacy of anolyte as a disinfectant for textiles.

She describes the process: “During electrochemical activation, a dilute solution of natrium chloride/salt passes through a cylindrical electrolytic cell where the anodic and cathodic chambers are separated. Two separate streams of electrochemically activated water are produced. Anolyte as water was produced at the positive electrode and has a low pH, high oxidation-reduction potential and contains dissolved chloride, oxygen, and hydroxyl radical. It also has an antimicrobial effect.”

The benefits of this process are in line with her enthusiasm for environmental conservation. 

According to Dr Vermaas, the amount of water and chemicals used to clean textile articles is massive. “Chemicals used to disinfect, for example, hospital laundry, are hazardous. Not all laundries in the industry have a closed loop system or try to remove the chemicals before the wastewater is discarded.”

“Different amounts of detergents have various effects on our fauna and flora. Due to their low biodegradability, toxicity, and high absorbance of particles, detergents can reduce the natural water quality, cause pH changes in soil and water, lead to eutrophication (too many nutrients), reduce light transmission, and increase salinity in water sources.”

“But with the catholyte and anolyte process, water returns to its original status, which means that the water solution becomes inactive again after production where it existed in a metastable state while containing many free radicals and a variety of molecules for 48 hours. Thus, no chemicals are left in the wastewater. The water can therefore be recycled, not as potable water but, for example, to flush toilets or to water plants.

“We should do what we can to save water,” she says. 

Should you, like Dr Vermaas, also feel strongly about protecting the environment and want to obtain one of these machines that leaves your washing clean and fresh without the use of any detergents, you will be able to find such an appliance in South Arica. However, it does not come cheap. “It is a bit costly for residential use, but might be more accessible in the future,” states Dr Vermaas, who is of the opinion that it is a more sustainable option for commercial laundries.

Detergency properties and colourfastness 

Recently, more research has been conducted on this topic, but with a focus on the detergency properties of the catholyte to clean different textile fibres (natural and synthetic). Catholyte, she explains, is water produced at the negative electrode with a high pH, low oxidation-reduction potential, containing alkaline minerals. It also has surface active agents that increase the wetting properties, and it is an antioxidant. 

“A master’s student in the department, Ketshepileone Matlhoko, will be submitting her dissertation at the end of November on the possibility of using the catholyte as a scouring agent to clean raw wool,” says Dr Vermaas. 

The department is also conducting studies to investigate the influence of both catholyte and anolyte on colourfastness.

*Graphic: Production of electrolysed water (Nakae and Indaba, 2000). Diagram: Supplied



News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept